Clinical Rheumatology

, Volume 28, Issue 4, pp 475–478 | Cite as

Evaluating obesity in fibromyalgia: neuroendocrine biomarkers, symptoms, and functions

  • Akiko OkifujiEmail author
  • David H. Bradshaw
  • Chrisana Olson
Brief Report


The aim of this study was to investigate the associations between obesity and fibromyalgia syndrome (FMS). This study was conducted at the University of Utah Pain Management and Research Center, Salt Lake City, Utah. Thirty-eight FMS patients were included in this study. Neuroendocrine indices (catecholamines, cortisol, C-reactive protein [CRP], and interleukin-6), symptom measures (Fibromyalgia Impact Questionnaire), sleep indices (Actigraph), and physical functioning (treadmill testing) were measured. Body mass index (BMI) provided the primary indicator of obesity. Approximately 50% of the patients were obese and an additional 21% were overweight. Strong positive associations were found between BMI and levels of IL-6 (r = 0.52) and epinephrine (r = 0.54), and somewhat weaker associations with cortisol (r = 0.32) and CRP (r = 0.37). BMI was also related to maximal heart rate (r = 0.33) and inversely related to distance walked (r = −0.41). BMI was associated with disturbed sleep: total sleep time (r = −0.56) and sleep efficiency (r = −0.44). No associations between self-reported symptoms and BMI were found. This study provides preliminary evidence suggesting that obesity plays a role in FMS-related dysfunction.


Catecholamine Cortisol Cytokine Fibromyalgia Obesity Sleep 



The preparation of this manuscript was supported by the NIAMS grant (R01 AR 48888) and University of Utah Catalyst Grant awarded to the first author. The authors would like to express their gratitude to Reiko Mitsunaga RN, Diana Mayer, and Sarah Featherstone for their assistance and coordination for the project.




  1. 1.
    White KP et al (1999) The London Fibromyalgia Epidemiology Study: the prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol 26(7):1570–1576PubMedGoogle Scholar
  2. 2.
    Wolfe F et al (1990) The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee [see comments]. Arthritis Rheum 33(2):160–172PubMedCrossRefGoogle Scholar
  3. 3.
    Penrod JR et al (2004) Health services costs and their determinants in women with fibromyalgia. J Rheumatol 31(7):1391–1398PubMedGoogle Scholar
  4. 4.
    Arendt-Nielsen L, Graven-Nielsen T (2003) Central sensitization in fibromyalgia and other musculoskeletal disorders. Curr Pain Headache Rep 7(5):355–361PubMedCrossRefGoogle Scholar
  5. 5.
    Okifuji A, Ashburn M (2001) Fibromyalgia syndrome: toward an integration of the literature. Crit Rev Phys Rehabil Med 13(1):27–54Google Scholar
  6. 6.
    Wallace DJ (2006) Is there a role for cytokine based therapies in fibromyalgia. Curr Pharm Des 12(1):17–22PubMedCrossRefGoogle Scholar
  7. 7.
    Bjorntorp P, Rosmond R (2000) Neuroendocrine abnormalities in visceral obesity. Int J Obes Relat Metab Disord 24(Suppl 2):S80–S85PubMedGoogle Scholar
  8. 8.
    Roth J et al (2004) The obesity pandemic: where have we been and where are we going? Obes Res 12(Suppl 2):88S–101SPubMedCrossRefGoogle Scholar
  9. 9.
    Bluher M et al (2005) Association of interleukin-6, C-reactive protein, interleukin-10 and adiponectin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism. Exp Clin Endocrinol Diabetes 113(9):534–537PubMedCrossRefGoogle Scholar
  10. 10.
    Yunus MB, Arslan S, Aldag JC (2002) Relationship between body mass index and fibromyalgia features. Scand J Rheumatol 31(1):27–31PubMedCrossRefGoogle Scholar
  11. 11.
    Peres MF et al (2005) Primary headaches in obese patients. Arq Neuropsiquiatr 63(4):931–933PubMedGoogle Scholar
  12. 12.
    Bigal ME, Liberman JN, Lipton RB (2006) Obesity and migraine: a population study. Neurology 66(4):545–550PubMedCrossRefGoogle Scholar
  13. 13.
    Lake JK, Power C, Cole TJ (2000) Back pain and obesity in the 1958 British birth cohort. cause or effect? J Clin Epidemiol 53(3):245–250PubMedCrossRefGoogle Scholar
  14. 14.
    Okifuji A et al (1997) A standardized manual tender point survey. I. Development and determination of a threshold point for the identification of positive tender points in fibromyalgia syndrome. J Rheumatol 24(2):377–383PubMedGoogle Scholar
  15. 15.
    American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Press, Washington, DCGoogle Scholar
  16. 16.
    Bennett R (2005) The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clin Exp Rheumatol 23(5 Suppl 39):S154–S162PubMedGoogle Scholar
  17. 17.
    Sadeh A et al (1989) Actigraphically based automatic bedtime sleep–wake scoring: validity and clinical application. J Ambul Monit 2:209–216Google Scholar
  18. 18.
    Hedley AA et al (2004) Prevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002. JAMA 291(23):2847–2850PubMedCrossRefGoogle Scholar
  19. 19.
    Busch AJ et al (2008) Exercise for fibromyalgia: a systematic review. J Rheumatol 35(6):1130–1144PubMedGoogle Scholar
  20. 20.
    Moldofsky H (2008) The significance, assessment, and management of nonrestorative sleep in fibromyalgia syndrome. CNS Spectr 13(3 Suppl 5):22–26PubMedGoogle Scholar

Copyright information

© Clinical Rheumatology 2009

Authors and Affiliations

  • Akiko Okifuji
    • 1
    Email author
  • David H. Bradshaw
    • 1
  • Chrisana Olson
    • 1
  1. 1.Pain Research and Management Center, Department of AnesthesiologyUniversity of UtahSalt Lake CityUSA

Personalised recommendations